Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service coronary intervention (PCI) cases in Utah: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (254 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 35 | 2,029 | 41% |
| 2020 | 35 | 1,924 | 44% |
| 2021 | 35 | 1,805 | 48% |
| 2022 | 36 | 1,685 | 51% |
| 2023 | 35 | 1,669 | 54% |
| 2024 | 33 | 1,541 | 57% |
| 2025 from claims | – | 1,494 1,371–1,581 | 59% |
| 2026 forecast | – | 1,503 1,323–1,735 | 60% |
| 2027 forecast | – | 1,514 1,294–1,804 | 61% |
| 2028 forecast | – | 1,524 1,271–1,866 | 62% |
| 2029 forecast | – | 1,533 1,252–1,922 | 62% |
| 2030 forecast | – | 1,541 1,235–1,975 | 63% |
Angioplasty, stenting, atherectomy, intravascular imaging. Professional codes (what the surgeon bills): CPT 92920, 92928, 92933, 92937, 92941, 92943; the hospital bills MS-DRG 246, 247, 248, 249, 321, 322, 323, 324, 325, 318, 359, 360.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 52% of the cases CMS names in Utah; 21 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 55% inpatient hospital, 45% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 390 | 17,678−4.1%/yr | −4.1%/yr | 4.3 | 0% | 19,700 in 2030+1.8%/yr |
| Arizona | 142 | 5,873−3.4%/yr | −3.4%/yr | 6.5 | 17% | 6,410 in 2030+1.5%/yr |
| Washington | 110 | 4,758−3.4%/yr | −3.4%/yr | 5.1 | 0% | 4,980 in 2030+0.7%/yr |
| Colorado | 63 | 2,688−3.7%/yr | −3.7%/yr | 4.5 | 1% | 3,050 in 2030+2.1%/yr |
| Nevada | 41 | 1,817−3%/yr | −3%/yr | 5.1 | 0% | 1,970 in 2030+1.4%/yr |
| Oregon | 40 | 1,758−7.7%/yr | −7.7%/yr | 3.4 | 2% | 1,840 in 2030+0.7%/yr |
| Montana | 18 | 1,037−8.8%/yr | −8.8%/yr | 4.9 | 0% | 1,380 in 2030+4.8%/yr |
| New Mexico | 18 | 1,021−9%/yr | −9%/yr | 3.6 | 0% | 1,030 in 2030+0.2%/yr |
| Idaho | 23 | 908−8.2%/yr | −8.2%/yr | 3.7 | 0% | 1,170 in 2030+4.3%/yr |
| Alaska | 9 | 512−4.6%/yr | −4.6%/yr | 4.2 | 0% | 550 in 2030+1.2%/yr |
| Hawaii | 9 | 344−2.3%/yr | −2.3%/yr | 2.1 | 0% | 570 in 2030+8.7%/yr |
| Wyoming | 3 | 218−9.7%/yr | −9.7%/yr | 1.9 | 0% | 210 in 2030−0.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Structural heart (TAVR, TEER) | 21 | 422−1.7%/yr | −1.7%/yr | 1.61.1× | 0% | 410 in 2030−0.3%/yr |
Coronary intervention (PCI) in every state, and its device makers · Every procedure market in Utah · Every state · Compare with California
Johnson & Johnson MedTech leads with 49% of company spending on these surgeons in 2025, +26 pts on 2024.
In 2025, 9 companies reported engagement with Utah’s surgeons worth $15K in consulting, speaking, meals and travel tied to these products, about $449 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 38 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.